A Phase 3 Randomized, Double-blind Study Of Pf-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-line Treatment Of Patients With Her2-positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS B327-02
- Sponsors Pfizer
- 12 Sep 2017 Results of primary analysis (data cut off 24 August 2016) presented at the 42nd European Society for Medical Oncology Congress
- 10 Sep 2017 Positive pivotal data from this study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, according to a Pfizer media release.
- 10 Sep 2017 Results published in a Pfizer Media Release.